(Q42536101)

1 November 2017

Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats (English)

1 reference

1 November 2017

0 references

0 references

Gorriti MA

1

1 reference

1 November 2017

Rodríguez de Fonseca F

series ordinal

2

1 reference

1 November 2017

Navarro M

series ordinal

3

1 reference

1 November 2017

Palomo T

series ordinal

4

1 reference

1 November 2017

language of work or name

English

0 references

publication date

1 January 1999

1 reference

European Journal of Pharmacology

1 November 2017

1 reference

1 November 2017

365

1 reference

1 November 2017

133-142

1 reference

1 November 2017

2-3

1 reference

CANNABIS AND SCHIZOPHRENIA A Longitudinal Study of Swedish Conscripts

1 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Positive and negative schizophrenic symptoms and the role of dopamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Regional brain homovanillic acid following delta 9-tetrahydrocannabinol and cocaine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Hypothalamic-pituitary-adrenal axis hyperactivity and psychosis: recovery during an 8-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Importance of the noradrenaline-dopamine coupling in the locomotor activating effects of D-amphetamine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Isolation and structure of a brain constituent that binds to the cannabinoid receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Marijuana's interaction with brain reward systems: update 1991.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Modulation of neurotransmission by cannabinoids in the basal ganglia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Interaction between ?9-Tetrahydrocannabinol and d-amphetamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Cannabinoid receptor localization in brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Neuronal localization of cannabinoid receptors in the basal ganglia of the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Pharmacology of cannabinoid receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Cannabis and neuroleptic agents in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Drug abuse: hedonic homeostatic dysregulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Corticosterone elevation mediated centrally by Δ1-tetrahydrocannabinol in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Life events-induced decrease of corticosteroid type I receptors is associated with reduced corticosterone feedback and enhanced vulnerability to amphetamine self-administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

The effects of psychotropic drugs on exploratory and stereotyped behaviour of rats studied on a hole-board

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Structure of a cannabinoid receptor and functional expression of the cloned cDNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Tetrahydrocannabinol potentiates reserpine-induced hypokinesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Comparative effects of tetrahydrocannabinol on psychostimulant-induced behaviors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

An acute dose of delta 9-tetrahydrocannabinol affects behavioral and neurochemical indices of mesolimbic dopaminergic activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Motor disturbances induced by an acute dose of delta 9-tetrahydrocannabinol: possible involvement of nigrostriatal dopaminergic alterations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

The effects of delta 9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: an in vivo electrochemical and in vivo microdialysis study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Pathophysiological basis of vulnerability to drug abuse: role of an interaction between stress, glucocorticoids, and dopaminergic neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Factors that predict individual vulnerability to amphetamine self-administration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Suppression of glucocorticoid secretion and antipsychotic drugs have similar effects on the mesolimbic dopaminergic transmission.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Interactions of delta9-tetrahydrocannabinol with d-amphetamine, cocaine, and nicotine in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Sensitization of cocaine-stimulated increase in extracellular levels of corticotropin-releasing factor from the rat amygdala after repeated administration as determined by intracranial microdialysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Effects of delta-9-tetrahydrocannabinol exposure on adrenal medullary function: Evidence of an acute effect and development of tolerance in chronic treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Acute effects of delta-9-tetrahydrocannabinol on dopaminergic activity in several rat brain areas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Repeated stimulation of D1 dopamine receptors enhances (-)-11-hydroxy-delta 8-tetrahydrocannabinol-dimethyl-heptyl-induced catalepsy in male rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Differential effects of chronic treatment with either dopamine D1 or D2 receptor agonists on the acute neuroendocrine actions of the highly potent synthetic cannabinoid HU-210 in male rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB1 receptor ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900851-6

10.1016/S0014-2999(98)00851-6

7 January 2021

Identifiers

DOI

1 reference

1 November 2017

1 reference